Guideline Recommendations for Managing CKD Stage G3a‑G3b with Rapid eGFR Decline

Diagnostic Priorities

Obtain a urine albumin‑to‑creatinine ratio (ACR) immediately to stratify risk and guide intensity of nephroprotective therapy (Grade 1 recommendation) 1.
Confirm the eGFR decline with a cystatin‑C‑based estimate when the laboratory notes that values in the 45‑59 mL/min/1.73 m² range require confirmation (Grade 1 recommendation) 1.
Screen for reversible acute factors such as volume depletion, recent NSAID use, contrast exposure, or urinary obstruction before attributing the decline to chronic progression (Grade 2 recommendation) 4.
Measure HbA1c promptly to determine whether impaired fasting glucose reflects pre‑diabetes or undiagnosed type 2 diabetes (Grade 1 recommendation) 5.

Start an SGLT2 inhibitor (empagliflozin 10 mg daily, canagliflozin 100 mg daily, or dapagliflozin 10 mg daily) irrespective of diabetes status when eGFR ≥ 20 mL/min/1.73 m² (Grade 1A) 1.
Continue the SGLT2 inhibitor even if eGFR falls below 20 mL/min/1.73 m² (Grade 1A) 6.
Initiate or uptitrate an ACE inhibitor or ARB to the maximum tolerated dose (e.g., lisinopril 40 mg daily, enalapril 20 mg twice daily, losartan 100 mg daily) (Grade 1B) 1.
Monitor serum creatinine and potassium 2–4 weeks after starting ACE/ARB; a rise in creatinine up to 30 % is expected and acceptable (Grade 1B) 2.

Prescribe an SGLT2 inhibitor (same dosing as above). Strong recommendation for patients with diabetes (Grade 1A); moderate recommendation for non‑diabetic patients (Grade 2B) 1.
Consider ACE/ARB therapy: Grade 1B if diabetes is present, Grade 2C if not 1.

SGLT2 inhibitor use depends on diabetes status: Grade 1A for diabetic patients; Grade 2B for non‑diabetic patients with eGFR ≈ 45‑47 mL/min/1.73 m² (Grade 2B) 1.
Do not initiate RAS inhibition for primary prevention when blood pressure is normal and ACR < 30 mg/g (Grade 1 recommendation) 3.

Add finerenone (non‑steroidal mineralocorticoid receptor antagonist) when ACR > 30 mg/g despite maximally tolerated ACE/ARB and SGLT2 inhibitor, provided eGFR > 25 mL/min/1.73 m² and serum potassium is ≤ 5.5 mmol/L (Grade 2A) 1.
- Dose 10 mg daily if eGFR 25‑59 mL/min/1.73 m²; 20 mg daily if eGFR ≥ 60 mL/min/1.73 m² 1.
Consider semaglutide for added kidney and cardiovascular protection in patients with confirmed diabetes (Grade 1A) 5.

Short‑term (2‑4 weeks after any medication change): check serum creatinine, potassium, and blood pressure; do not discontinue ACE/ARB if creatinine rise ≤ 30 % (Grade 1 recommendation) 2.
Long‑term: repeat eGFR and ACR every 3‑6 months; aim for ≥ 30 % reduction in albuminuria when baseline ACR ≥ 300 mg/g (Grade 1 recommendation) 3.

Expected eGFR dip with SGLT2 inhibitors of 3‑5 mL/min/1.73 m² is hemodynamic and predicts long‑term benefit; do not stop the drug for this change (Grade 1 recommendation) 1.
RAS inhibitor–related creatinine rise up to 30 % reflects reduced intraglomerular pressure and is nephroprotective; continue therapy unless rise exceeds 30 % or other safety thresholds are met (Grade 1 recommendation) 1.
Temporarily withhold SGLT2 inhibitors during prolonged fasting, surgery, critical illness, or when risk of ketoacidosis exists (Grade 2 recommendation) 6.
Discontinue or reduce ACE/ARB only for:
- creatinine increase > 30 % within 4 weeks,
- symptomatic hypotension,
- uncontrolled hyperkalemia despite potassium‑lowering measures (Grade 1 recommendation) 2.
Avoid triple RAS blockade (ACE + ARB + direct renin inhibitor) and dual ACE + ARB therapy because of increased harm (Grade 1 recommendation) 1.

Target blood pressure < 120/80 mmHg if tolerated, as aggressive control slows CKD progression (Grade 1 recommendation) 5.
Start statin therapy for lipid management in adults with CKD and age ≥ 50 years (Grade 1 recommendation) 7.
Encourage smoking cessation (Grade 1 recommendation) 6.
Aim for HbA1c < 7 % in patients with diabetes (Grade 1 recommendation) 7.

Refer when eGFR continues to decline and falls below 30 mL/min/1.73 m², when albuminuria rises despite optimal therapy, or when CKD etiology remains unclear (Grade 1 recommendation) 3.